Covid-19 Vaccination Options for Immunosuppressed Cancer Patients
Open Access
- 29 January 2021
- journal article
- Published by Universitas Airlangga in Jurnal Berkala Epidemiologi
- Vol. 9 (1), 1-9
- https://doi.org/10.20473/jbe.v9i12021.1-9
Abstract
Background: Currently, many COVID-19 vaccine candidates are being developed to end the pandemic; however, immunosuppressed cancer patients have been excluded from the participating criteria. It is important that they are able to examine their options for achieving immunity against COVID-19. Purpose: This review aims to discuss the available options that can be taken to vaccinate immunosuppressed cancer patients when no vaccine is being developed for their safety. Method: A literature study was conducted using Google Scholar, DOAJ, and GARUDA Library on November 2, 2020, focusing on articles examining vaccination guidelines for immunosuppressed cancer patients. Results: The search found 200 articles, which were curated to obtain 13 articles that satisfied all inclusion criteria. These consist of four guidelines, five reviews, and four research articles. Based on the literature, immunosuppressed cancer patients have the option to use the vaccines currently under development, with precautions set for live attenuated and potentially infectious vaccines. Vaccination timing also needs to be adjusted so as to fall at a certain time before or after the immunosuppressive condition. Moreover, a more complete COVID-19 immunity can be achieved through a synergy between individual vaccination and the construction of herd immunity. Conclusion: Most of the vaccines currently under development may be safe for cancer patients, being mindful of several considerations. Here, herd immunity can serve as a complement to individual immunity.Keywords
This publication has 28 references indexed in Scilit:
- Vaccination recommendations for the adult immunosuppressed patient: A systematic review and comprehensive field synopsisJournal of Autoimmunity, 2017
- Influenza vaccination in adult patients with solid tumours treated with chemotherapyEuropean Journal of Cancer, 2017
- Recommended immunization schedules for adults: Clinical practice guidelines by the Escmid Vaccine Study Group (EVASG), European Geriatric Medicine Society (EUGMS) and the World Association for Infectious Diseases and Immunological Disorders (WAidid)Human Vaccines & Immunotherapeutics, 2016
- Immunogenicity and clinical effectiveness of the trivalent inactivated influenza vaccine in immunocompromised children undergoing treatment for cancerCancer Medicine, 2015
- Antiviral prophylaxis in patients with solid tumours and haematological malignancies—update of the Guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society for Hematology and Medical Oncology (DGHO)Annals of Hematology, 2015
- Practical review of immunizations in adult patients with cancerHuman Vaccines & Immunotherapeutics, 2015
- Immunization in cancer patients: Where we standPharmacological Research, 2014
- Acute myeloid leukemia creates an arginase-dependent immunosuppressive microenvironmentBlood, 2013
- Safety and Immunogenicity of Live Attenuated and Inactivated Influenza Vaccines in Children With CancerThe Journal of Infectious Diseases, 2011
- Immunogenicity of a two‐dose regime of varicella vaccine in children with cancersEuropean Journal of Haematology, 2004